Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacabrutideg in Chronic Spontaneous Urticaria and Healthy Participants
NCT07005713Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jul 2025
- Primary completion
- Nov 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised trial of tacabrutideg in chronic spontaneous urticaria (CSU) (3 arms), sponsored by BeOne Medicines. Primary endpoints: Adverse Events at 6 weeks, Maximum observed plasma concentration at 10 weeks and 8 more. Started Jul 2025; status: recruiting.
02
Drugs
tacabrutideg
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07005713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005713.